Clinical Trial Update: A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

A Phase II trial compared low- and high-dose alemtuzumab with high-dose Rebif in patients with early active relapsing-remitting multiple sclerosis; the study re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Rebif (interferon beta-1a)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Status: COMPLETED | Results posted: 2009-08-25